Loading clinical trials...
Loading clinical trials...
A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors
Conditions
Interventions
MEDI7247
Locations
3
United States
Research Site
Huntersville, North Carolina, United States
Research Site
Nashville, Tennessee, United States
Research Site
Toronto, Ontario, Canada
Start Date
December 20, 2018
Primary Completion Date
December 10, 2019
Completion Date
December 10, 2019
Last Updated
December 30, 2019
NCT07510724
NCT04080804
NCT06630780
NCT06943820
NCT06673693
NCT05473156
Lead Sponsor
MedImmune LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions